Sm08502-onc-01

Author: eqze

August undefined, 2024

WebbSM08502-ONC-01: A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects with … Webb30 jan. 2024 · Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and …

Meeting a new mechanism Drug Discovery News

Webb31 mars 2024 · In an iterative screening campaign of >1500 compounds, SM08502 was developed as a small-molecule CLK inhibitor with IC 50 values of 0.002 μM for CLK2 and … http://www.usalifesciences.com/us/portal/news_details.php?news_id=28606851k$SnKVXke2weSNs fishelll方法

EPIC SCIENCES AND BIOSPLICE THERAPEUTICS ANNOUNCE …

Webb16 dec. 2024 · Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and … Webb6 jan. 2024 · Mel J. Yeates. SAN DIEGO—In late 2024, Samumed, LLC noted the publication of data demonstrating a novel mechanism of action for SM08502 in preclinical … Webb26 maj 2024 · Conclusions: In preclinical CRC models, SM08502 was a potent inhibitor of Wnt pathway signaling and gene expression. It showed strong antitumor activity in … canada christian college jobs

(PDF) The CLK inhibitor SM08502 induces anti-tumor

WO2024023840A1 - Novel tumor-specific antigens for cancer …

WebbApply to this Phase 1 clinical trial treating Non-small Cell Lung Cancer, Colorectal Carcinoma (CRC), Castration-resistant Prostate Cancer. Get access to cutting edge … WebbAs part of this relationship, Biosplice will leverage Epic's comprehensive platform to characterize drug activity and patient response in Biosplice's SM08502-ONC-01 and SM08502-ONC-03 trials. "We are excited to partner with Epic in our biomarker development program" states Darrin Beaupre , MD, PhD, Chief Medical Officer, Oncology at Biosplice … fishel labWebb11 dec. 2024 · SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Samumed, today announced the dosing of the first cancer patient in its Phase 1 trial of SM08502, a small … canada christine lydon

"WebbSM08502-ONC-01: A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects with … " - Sm08502-onc-01

Sm08502-onc-01

EPIC SCIENCES AND BIOSPLICE THERAPEUTICS ANNOUNCE …

Webb29 sep. 2024 · add_box. SAN DIEGO, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering … Webb27 jan. 2024 · As part of this relationship, Biosplice will leverage Epic’s comprehensive platform to characterize drug activity and patient response in Biosplice’s SM08502-ONC …

Did you know?

WebbThis study is an open-label, multi-center, dose-escalation, dose-finding and expansion study in adult subjects with advanced solid tumors for whom no standard therapy is available. … Webb13 dec. 2024 · SM08502 inhibited cell viability in all 14 cell lines (regardless of KRAS status) (EC 50 =0.072-0.526 μM). In Capan-1, HPAFII, and Panc1 cells, 1 μM SM08502 …

Webb17 nov. 2024 · Drug: SM08502 Study Type Interventional Enrollment (Actual) 82 Phase Phase 1 Contacts and Locations This section provides the contact details for those … WebbSAN DIEGO, Jan. 27, 2024 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CL

WebbAs part of this relationship, Biosplice will leverage Epic's comprehensive platform to characterize drug activity and patient response in Biosplice's SM08502-ONC-01 and … Webb[VIRTUAL] SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt and cyclin D-CDK4/6-RB pathway inhibition in hormone-receptor-positive (HR+) breast cancer models (AACR-II 2024)

Webb1 aug. 2024 · HEC265, SNGM, and Ishikawa-S33Y tumors all had significantly lower tumor volumes with combination of SM08502 and paclitaxel compared to single-agent …

Webb31 mars 2024 · SM08502 is a first-in-class CLK inhibitor being investigated in a Phase 1 clinical trial for subjects with advanced solid tumors (NCT03355066). Keywords: … canada christian kids programsWebb27 jan. 2024 · As part of this relationship, Biosplice will leverage Epic's comprehensive platform to characterize drug activity and patient response in Biosplice's SM08502-ONC-01 and SM08502-ONC-03 trials. "We are excited to partner with Epic in our biomarker development program" states Darrin Beaupre , MD, PhD, Chief Medical Officer, Oncology … fishell auctionWebb6 apr. 2024 · SM08502 (cirtuvivint) is a novel pan CDC-like kinase (CLK) and Dual specificity tyrosine kinase (DYRK) inhibitor that targets mRNA splicing and is optimized … can a dachshund be a service dogWebb27 jan. 2024 · SAN DIEGO, Jan. 27, 2024 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK … canada christmas foodWebb2 okt. 2024 · SAN DIEGO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today the publication of data demonstrating a novel mechanism of action for SM08502 … canada christmas gift basketshttp://www.usalifesciences.com/us/portal/news_details.php?news_id=28606851k$SnKVXke2weSNs canada chinese social credit systemWebbSM08502, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects as Monotherapy and in … fishel las vegas